2014


To access this material please log in or register

Register Authorize
2014/№2

Natriuretic peptide in acute coronary syndrome associated with chronic kidney disease

Shalenkova M. A., Mikhaylova Z. D., Manyukova E. T., Klimkin P. F.

Keywords: acute coronary syndrome, chronic kidney disease

DOI: 10.18087/rhj.2014.2.1914

Background. Natriuretic peptides (BNP, NT-proBNP) are independent predictive factors for CHF, MI and death in acute coronary syndrome (ACS). NT-proBNP levels may be also increased in chronic kidney disease (CKD). Aim. To evaluate the significance of NTproBNP level in ACS associated with pre-dialysis CKD. Materials and methods. 153 patients with ACS were evaluated. 64 patients had unstable angina (UA); 89 patients had MI. Blood levels of NT-proBNP and creatinine were measured in all patients on days 1–3 of hospitalization. Glomerular filtration rate (GFR) was calculated using the MDRD and CKD-EPI equations. Results. A greater proportion of ACS patients had stage 2 CKD independent on their age, gender, ACS type, and cardiovascular complications. Median (Ме) NT-proBNP linearly increased at more advanced CKD stages from 203 [71; 355] in MI patients with stage 1 CKD to 8310 [769; 13510] in MI patients with stage 4 CKD. NT-proBNP levels significantly inversely correlated with GFR values in patients with MI (R= –0.326, p=0.003) and UA (R= –0.352, p=0.007). Conclusion. A greater proportion of patients with ACS had mild impairment of renal function (stage 2 CKD in 53 %). NT-proBNP levels correlated with CKD severity.
  1. Brooks MM, Jones RH, Bach RG et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascula­rization investigation (BARI) randomized trial and registry. For the BARI Investigators. Circulation. 2000 Jun 13;101 (23):2682–9.
  2. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352 (12):1179–89.
  3. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Российские рекомендации разработаны Комитетом экспертов Всероссийского научного общества кардиологов и Научным обществом нефрологов России. Приложение 3 к журналу «Кардиоваскулярная терапия и профилактика». 2008;7 (6):41.
  4. Austin WJ, Bhalla V, Hernandez-Arce I et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol. 2006 Oct;126 (4):506–12.
  5. Ronco C, McCullough P, Anker SD et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010 Mar;31 (6):703–11.
  6. Руденко Т. Е., Кутырина И. М., Васильева М. П. Натрийурети­­ческие пептиды: диагностическое и прогностическое значения при хронической болезни почек. Клиническая нефрология. 2013;2:5–9.
  7. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. Нефрология. 2012;16 (1):91–108.
Shalenkova M. A., Mikhaylova Z. D., Manyukova E. T. et al. Natriuretic peptide in acute coronary syndrome associated with chronic kidney disease. Russian Heart Journal. 2014;76 (2):85–88

To access this material please log in or register

Register Authorize
Ru En